Drug Profile
BBI 3000
Alternative Names: BBI-3000Latest Information Update: 25 Sep 2023
Price :
$50
*
At a glance
- Originator Undisclosed
- Developer Fresh Tracks Therapeutics
- Class Retinoids; Small molecules
- Mechanism of Action Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne; Cutaneous T-cell lymphoma